Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Millions of people with hypothyroidism depend on levothyroxine every day to replace the thyroid hormone their body cannot produce.

Now, the U.S. Food and Drug Administration (FDA) has announced a nationwide recall of certain batches of levothyroxine sodium tablets after they were found to be subpotent, meaning they contain less active medication than stated on the label.

Experts caution that ingesting a lower-than-prescribed dose could allow hypothyroidism symptoms to return, particularly in vulnerable groups like pregnant women, infants, and people with thyroid cancer.

Why Did FDA Recall Levothyroxine?

The FDA has issued a Class II recall for specific lots of levothyroxine sodium tablets distributed by Major Pharmaceuticals. Testing found that the recalled tablets were below the approved potency specification, meaning they may not deliver the intended amount of thyroid hormone.

The recall affects multiple strengths packaged in 100-tablet cartons and 10-count blister packs. Dosages involved include 25 mcg, 50 mcg, 75 mcg, 88 mcg, 112 mcg, 125 mcg and 150 mcg.

The FDA has categorized the action as a Class II recall. According to the agency, a Class II recall means: "Use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

This means the recall is important but does not come under FDA's highest-risk category.

Also read: Is Your Allergy Medicine Safe? FDA Recalls Antihistamine Tablets Over Life-Threatening Contamination Concerns

Why A Subpotent Thyroid Medicine A Concern?

Even relatively small differences in levothyroxine dose can affect how well the medicine works. If they contain less hormone than needed, patients may receive insufficient thyroid replacement. Possible consequences include:

• Fatigue
• Weight gain
• Feeling unusually cold
• Constipation
• Depression or low mood
• Brain fog
• Dry skin
• Slower heart rate

In some higher-risk individuals, inadequate thyroid hormone replacement could have more severe consequences, including worsening hypothyroidism or interference with thyroid cancer treatment.

Also read: CDC's 'Vaccines Do Not Cause Autism' Webpage Sparks Debate; Republican Senator Seeks Clarity

What Does This Recall Mean For Patients?

Because thyroid hormone influences nearly every organ system, taking the correct dose consistently is essential.

Also read: Montelukast Mental Health Warning Still Largely Overlooked By Psychiatrists

Do not stop taking levothyroxine on your own. Stopping thyroid medication suddenly can lead to worsening hypothyroidism and other complications. Instead, patients should:

• Check whether their medication's lot number matches the recalled batches.
• Contact your pharmacist or physician.
• Obtain a replacement if their medication is affected.
• Continue treatment unless instructed otherwise by a healthcare professional.

Other Recently Recalled Medications

The FDA also announced recently that it is recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg made by India-based company Unique Pharmaceutical Laboratories due to potential cross-contamination with ranitidine, a medication used to treat heartburn and stomach ulcers.

Although Unique Pharmaceutical Laboratories said it has not received any reports of adverse reactions related to the recalled tablets, the contamination could pose a serious risk for people who are allergic or hypersensitive to ranitidine.

The latest FDA recall serves as a reminder that quality control remains critical for medications taken every day. For anyone taking levothyroxine, experts recommend checking medication packaging against the FDA recall notice and speaking with a healthcare provider or pharmacist if there is any uncertainty.

Florida is once again reporting an increase in Hansen's disease (leprosy) cases, renewing attention to a disease that got eradicated decades ago.

While the infection remains rare in the United States, health officials say Florida continues to report one of the country's highest numbers of locally acquired cases, with recent infections concentrated in several Central Florida counties.

According to the Florida Department of Health, 17 cases of leprosy had been reported statewide through mid-July 2026, with multiple cases identified in Brevard, Lake, Orange, Seminole, Sumter, and Volusia counties.

Local health experts say the disease is uncommon but not unexpected in Florida, where environmental and wildlife factors contribute to its persistence.

Why Does Leprosy Still Exist In Florida?

Also read: WHO Declares Australia Free Of Trachoma: All About The Irreversible Blindness

Unlike many parts of the world where leprosy is associated human-to-human transmission, Florida has a unique risk factor: wild nine-banded armadillos.

Research has shown that armadillos are natural reservoirs of Mycobacterium leprae, the bacterium that causes leprosy.

Humans may become infected after frequent contact with infected armadillos or contaminated soil where the bacteria may persist. Experts emphasize that not every armadillo carries the bacteria.

Scientists also believe Florida has become endemic for leprosy, meaning the disease is now established locally rather than being introduced through international travel.

Increasing numbers of patients have reported no history of foreign travel or known contact with someone diagnosed with leprosy, suggesting local transmission is still prevalent.

All About Leprosy

Also read: Chile Becomes The First Country In Americas To Eliminate Leprosy, Says WHO

Leprosy, also known as Hansen's disease, is a chronic bacterial infection caused primarily by Mycobacterium leprae. The disease mainly affects:

• Skin
• Peripheral nerves
• Eyes
• Upper respiratory tract lining

If diagnosed early, it is completely curable. Delayed treatment, however, can result in permanent nerve damage, muscle weakness, and disability.

How Does It Spread?

Contrary to longstanding myths, leprosy is not highly contagious. Health experts say the infection usually spreads through prolonged, close contact with untreated individuals, likely via respiratory droplets.

Casual interactions like shaking hands, hugging, sharing meals, or sitting next to someone do not typically spread the disease.

The illness also has an unusually long incubation period, often taking 2 to 20 years before symptoms appear, making it difficult to identify exactly where and when an infection occurred. Early symptoms may include:

• Pale or reddish skin patches with reduced sensation
• Numbness in the hands or feet
• Tingling or nerve pain
• Muscle weakness
• Thickened peripheral nerves

Because symptoms develop gradually, many patients are diagnosed only after nerve damage has already begun.

Experts advise avoiding unnecessary handling of wild armadillos and seeking medical evaluation for persistent numb skin lesions, especially after possible exposure

Although leprosy is curable, its persistence in Florida highlights how infectious diseases can survive in animal reservoirs even after becoming rare in humans.

Public health experts say improving awareness among both doctors and the public is essential for early diagnosis, timely treatment, and preventing permanent disability.

The U.S. Centers for Disease Control and Prevention's (CDC) revised webpage on autism and vaccines has reignited debate over how health agencies should communicate scientific evidence.

Republican Senator Bill Cassidy slammed the agency's messaging while continuing to defend the overwhelming scientific evidence that vaccines do not cause autism.

CDC Makes Changes To Its Autism And Vaccine Webpage

The controversy was sparked on changes made to the CDC's autism webpage, which now states that the claim "vaccines do not cause autism" is "not an evidence-based claim" as studies have not ruled out every possible link between infant vaccines and autism.

The page also says the U.S. Department of Health and Human Services (HHS) is continuing to investigate the causes of autism.

The revised language represents a shift from the CDC's longstanding public messaging, which for years stated that extensive scientific research had found no causal relationship between vaccines and autism.

The changes have drawn criticism from scientists, physicians, and lawmakers who fear they could weaken public confidence in routine childhood immunization.

Also read: US FDA Identifies New Cyclospora Outbreak As Michigan Cases Top 7,000: Why Is The Source So Hard To Trace?

Republican Senator Bill Cassidy Reacts

Sen. Bill Cassidy, a Louisiana Republican, physician, and chairman of the Senate Health, Education, Labor and Pensions Committee, recently said discussions with CDC Director nominee Dr. Erica Schwartz and HHS officials led to what he described as a "good faith" revision of the webpage.

"As a sign of good faith, HHS modified the CDC's autism and vaccines webpage. There is more to do to repair the damage that has been done to the U.S. public health response, but this is a start," Cassidy said.

Cassidy had previously questioned whether future CDC leadership would protect scientific integrity and resist political pressure on vaccine policy during Schwartz's Senate confirmation hearing.

While Cassidy ultimately announced his support for Schwartz's nomination, he has continued to stress that the agency should responsibly communicate established scientific evidence regarding vaccines.

Also read: Legionnaires' Disease Claims 5th Life In New York City: Health Officials

Scientific Consensus Remains Intact

Despite the debate surrounding the CDC webpage, the broader scientific consensus has not changed.

Large studies conducted over several decades in multiple countries have consistently found no evidence that routine childhood vaccines cause autism.

Major medical organizations continue to support vaccination as one of the safest and most effective public health interventions.

Health experts have also warned that ambiguous or conflicting public health messaging could further affect vaccine confidence at a time when the United States is experiencing its highest number of measles cases in more than three decades, largely driven by declining childhood vaccination rates.

The controversy highlights the growing tension between political oversight and scientific communication within U.S. public health agencies.

For public health experts, the concern extends beyond a single webpage. They argue that how government agencies present scientific evidence can directly influence vaccine confidence, healthcare decisions, and efforts to prevent outbreaks of vaccine-preventable diseases.